Abstract: The present disclosure provides an unbalanced sample classification method and an unbalanced sample classification apparatus. The method includes: obtaining unbalanced sample data; calculating a sample contribution rate based on the sample data and the characteristic data; filtering out a part of the sample data within a preset sample contribution threshold according to the sample contribution rate to determine as target sample data; and inputting the target sample data into a sample classification model to calculate a sample classification result through a classification algorithm. By using two variables of the characteristic value contribution rate and the characteristic contribution rate, the characteristics and samples with low contribution rate for classification are eliminated to effectively reducing the processing of unbalanced sample data, and a machine learning classification algorithm can be used on this basis to adopt the effective characteristics or samples to achieve efficient classification.

Abstract: Systems and methods are provided for providing Response Time Compensation (RTC) by generating multiple overdrive look-up tables (LUTs) for a display device are described. In some embodiments, an Information Handling System (IHS) may include a controller and a memory coupled to the controller, the memory having program instructions stored thereon that, upon execution, cause the controller to generate multiple LUTs each having alternate grey levels selected to implement RTC in a Liquid Crystal Display (LCD), wherein the alternate grey levels of each of the LUTs is calculated, at least in part, by taking into account one of a plurality of pixel lines of a video stream.

Abstract: The present disclosure provides a method, a device and a computer readable storage medium for food risk traceability information classification.

Abstract: The present disclosure provides an unbalanced sample classification method and an unbalanced sample classification apparatus. The method includes: obtaining unbalanced sample data; calculating a sample contribution rate based on the sample data and the characteristic data; filtering out a part of the sample data within a preset sample contribution threshold according to the sample contribution rate to determine as target sample data; and inputting the target sample data into a sample classification model to calculate a sample classification result through a classification algorithm. By using two variables of the characteristic value contribution rate and the characteristic contribution rate, the characteristics and samples with low contribution rate for classification are eliminated to effectively reducing the processing of unbalanced sample data, and a machine learning classification algorithm can be used on this basis to adopt the effective characteristics or samples to achieve efficient classification.

Abstract: The present disclosure provides a method, a device and a computer readable storage medium for food risk traceability information classification.

Abstract: The present disclosure provides a humanized anti-BASIGIN antibody or antigen binding fragment thereof, which comprises heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 1; optionally further comprise light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 2. The present disclosure also provides a composition comprising the humanized anti-BASIGIN antibody or antigen binding fragment thereof, an isolated nucleic acid sequence encoding the humanized anti-BASIGIN antibody or antigen binding fragment thereof, a vector comprising the nucleic acid, a host cell comprising the vector, and use of the humanized anti-BASIGIN antibody or antigen binding fragment thereof.

Abstract: The present disclosure relates to a nucleotide sequence comprising the sequence of SEQ ID NO: 5, and/or sequence of SEQ ID NO: 6, vector and host cell line comprising the nucleotide. The present disclosure also relates to an antibody that binds to extracellular region of human CD147, wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2, and/or a light chain variable region having the amino acid sequence of SEQ ID NO: 1, and the antibody contains a glycoform lacking both fucose residues and xylose residues, pharmaceutical composition comprising the antibody or fragment thereof, the method of producing the antibody or fragment thereof, and use of the pharmaceutical composition in treatment of CD147 expression-related diseases.

Abstract: The present disclosure relates to a nucleotide sequence comprising the sequence of SEQ ID NO: 5, and/or sequence of SEQ ID NO: 6, vector and host cell line comprising the nucleotide. The present disclosure also relates to an antibody that binds to extracellular region of human CD147, wherein the antibody comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO: 2, and/or a light chain variable region having the amino acid sequence of SEQ ID NO: 1, and the antibody contains a glycoform lacking both fucose residues and xylose residues, pharmaceutical composition comprising the antibody or fragment thereof, the method of producing the antibody or fragment thereof, and use of the pharmaceutical composition in treatment of CD147 expression-related diseases.

Abstract: A crystal, a preparation method and 3D structure of CD147 extracellular region are provided. Such 3D structure is useful in the determination of the active site of CD147 extracellular region by computer modeling or molecular docking method. The crystal and/or 3D structure are useful in a structure-based drug design and the selection of an antibody, a ligand or an interacting molecule of CD 147 extracellular region.

Abstract: A crystal, a preparation method and 3D structure of CD147 extracellular region are provided. Such 3D structure is useful in the determination of the active site of CD147 extracellular region by computer modeling or molecular docking method. The crystal and/or 3D structure are useful in a structure-based drug design and the selection of an antibody, a ligand or an interacting molecule of CD 147 extracellular region.

Abstract: The present invention relates to the anti-human hepatocarcinoma McAb HAb18 heavy chain and light chain variable region genes, the polypeptides encoded by the same, as well as to their use in the preparation of a medicament for diagnosing and treating tumors or inflammation diseases. Based on the heavy chain and light chain variable region genes, various novel small molecule genetic engineering antibodies, including single chain antibodies, chimeric antibodies, Fab antibodies and the like can be constructed and expressed for the diagnosis and treatment of hepatoma.

Abstract: The present invention relates to use of HAb18G/CD147 molecule as target for designing antiviral antagonist and the antiviral antagonist designed by using such molecule, especially antagonist against SARS Coronavirus and AIDS virus HIV-1. Antagonist of the present invention includes antibody, polypeptide, immune complex, derivative, small molecule compound and so on, which is able to prevent SARS Coronavirus and AIDS virus (HIV-1) from invading host cell, thereby exerts its antagonistic antiviral effect. It is provided by in vitro experiment that such antagonist has inhibitory effect against SARS Coronavirus and AIDS virus (HIV-1), thus is potential antiviral candidate drug.

Abstract: The present invention relates to the anti-human hepatocarcinoma McAb HAb18 heavy chain and light chain variable region genes, the polypeptides encoded by the same, as well as to their use in the preparation of a medicament for diagnosing and treating tumors or inflammation diseases. Based on the heavy chain and light chain variable region genes, various novel small molecule genetic engineering antibodies, including single chain antibodies, chimeric antibodies, Fab antibodies and the like can be constructed and expressed for the diagnosis and treatment of hepatoma.

Abstract: The present invention relates to a new protein molecule HAb18G/CD147 which is derived from hepatocellular carcinoma tissue and can be used as a drug target. The invention also relates to the antisense RNA directed to HAb18G/CD147 transcript, and antagonistic peptides for HAb18G/CD147.